Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) will be reporting results this Thursday before market open. Here’s what to look for.

Bristol-Myers Squibb beat analysts’ revenue expectations last quarter, reporting revenues of $11.49 billion, up 2.5% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.

Is Bristol-Myers Squibb a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Bristol-Myers Squibb’s revenue to decline 6.3% year on year, a deceleration from its flat revenue in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Bristol-Myers Squibb has a history of exceeding Wall Street’s expectations.

With Bristol-Myers Squibb being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 4.4% on average over the last month. Bristol-Myers Squibb is up 8.7% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.